Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Extrastriatal degeneration correlates with deficits in the motor domain subscales of the UHDRS.

Galvez V, Ramírez-García G, Hernandez-Castillo CR, Bayliss L, Díaz R, Lopez-Titla MM, Campos-Romo A, Fernandez-Ruiz J.

J Neurol Sci. 2018 Feb 15;385:22-29. doi: 10.1016/j.jns.2017.11.040. Epub 2017 Dec 1.

PMID:
29406908
2.

Early grey matter changes in structural covariance networks in Huntington's disease.

Coppen EM, van der Grond J, Hafkemeijer A, Rombouts SA, Roos RA.

Neuroimage Clin. 2016 Oct 12;12:806-814. eCollection 2016.

3.

Clinical and genetic characteristics in patients with Huntington's disease from China.

Yang J, Chen K, Wei Q, Chen Y, Cao B, Burgunder JM, Shang HF.

Neurol Res. 2016 Oct;38(10):916-20. doi: 10.1080/01616412.2016.1214555. Epub 2016 Jul 29.

PMID:
27483361
4.

Grey matter volume loss is associated with specific clinical motor signs in Huntington's disease.

Coppen EM, Jacobs M, van den Berg-Huysmans AA, van der Grond J, Roos RAC.

Parkinsonism Relat Disord. 2018 Jan;46:56-61. doi: 10.1016/j.parkreldis.2017.11.001. Epub 2017 Nov 2.

PMID:
29128164
5.

Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat.

Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F.

J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):130-5. Epub 2007 Jul 5.

PMID:
17615168
6.

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.

Minkova L, Gregory S, Scahill RI, Abdulkadir A, Kaller CP, Peter J, Long JD, Stout JC, Reilmann R, Roos RA, Durr A, Leavitt BR, Tabrizi SJ, Klöppel S; TRACK-HD Investigators.

Neuroimage Clin. 2017 Oct 25;17:312-324. doi: 10.1016/j.nicl.2017.10.023. eCollection 2018.

7.

Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.

Gómez-Ansón B, Alegret M, Muñoz E, Monté GC, Alayrach E, Sánchez A, Boada M, Tolosa E.

Parkinsonism Relat Disord. 2009 Mar;15(3):213-9. doi: 10.1016/j.parkreldis.2008.05.010. Epub 2008 Jul 15.

PMID:
18632301
8.

Cerebellar abnormalities in Huntington's disease: a role in motor and psychiatric impairment?

Rees EM, Farmer R, Cole JH, Haider S, Durr A, Landwehrmeyer B, Scahill RI, Tabrizi SJ, Hobbs NZ.

Mov Disord. 2014 Nov;29(13):1648-54. doi: 10.1002/mds.25984. Epub 2014 Aug 13.

PMID:
25123926
9.

The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study.

Sánchez-Castañeda C, Squitieri F, Di Paola M, Dayan M, Petrollini M, Sabatini U.

Hum Brain Mapp. 2015 Jan;36(1):50-66. doi: 10.1002/hbm.22612. Epub 2014 Aug 21.

PMID:
25145324
10.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
11.

Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease.

Novak MJ, Warren JD, Henley SM, Draganski B, Frackowiak RS, Tabrizi SJ.

Brain. 2012 Apr;135(Pt 4):1165-79. doi: 10.1093/brain/aws024.

12.

Cerebellar Gray Matter Alterations in Huntington Disease: A Voxel-Based Morphometry Study.

de Azevedo PC, Guimarães RP, Piccinin CC, Piovesana LG, Campos LS, Zuiani JR, Tamashiro EM, Pinheiro G, Amato-Filho AC, Cendes F, Lopes-Cendes I, D'Abreu A.

Cerebellum. 2017 Dec;16(5-6):923-928. doi: 10.1007/s12311-017-0865-6.

PMID:
28528357
13.

Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.

Dogan I, Eickhoff SB, Schulz JB, Shah NJ, Laird AR, Fox PT, Reetz K.

Neurodegener Dis. 2013;12(1):23-35. doi: 10.1159/000339528. Epub 2012 Aug 23.

14.

Voxel Based Morphometry Alterations in Mal de Debarquement Syndrome.

Cha YH, Chakrapani S.

PLoS One. 2015 Aug 7;10(8):e0135021. doi: 10.1371/journal.pone.0135021. eCollection 2015.

15.

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.

Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, Alagille D, Morley TJ, Papin C, Papapetropoulos S, Waterhouse RN, Seibyl JP, Marek KL.

JAMA Neurol. 2014 Dec;71(12):1520-8. doi: 10.1001/jamaneurol.2014.1954.

PMID:
25322077
16.

Variation of selective gray and white matter atrophy in Huntington's disease.

Jech R, Klempír J, Vymazal J, Zidovská J, Klempírová O, Růzicka E, Roth J.

Mov Disord. 2007 Sep 15;22(12):1783-9.

PMID:
17579363
17.

[A voxel-based morphometric study on change of gray matter structures in cerebral palsy].

Wang Y, Wang H, Yu Y, Xu L, Chen Y, Wu D.

Zhonghua Er Ke Za Zhi. 2015 Sep;53(9):696-700. Chinese.

PMID:
26757971
18.

Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study.

Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J.

J Neurol Sci. 2005 Dec 15;239(1):11-9. Epub 2005 Sep 26.

PMID:
16185716
19.

Resting-state fMRI reveals potential neural correlates of impaired cognition in Huntington's disease.

Liu W, Yang J, Chen K, Luo C, Burgunder J, Gong Q, Shang H.

Parkinsonism Relat Disord. 2016 Jun;27:41-6. doi: 10.1016/j.parkreldis.2016.04.017. Epub 2016 Apr 21.

PMID:
27117563
20.

An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.

Vaccarino AL, Anderson K, Borowsky B, Duff K, Giuliano J, Guttman M, Ho AK, Orth M, Paulsen JS, Sills T, van Kammen DP, Evans KR; PREDICT-HD and REGISTRY Investigators Coordinators.

Mov Disord. 2011 Apr;26(5):877-84. doi: 10.1002/mds.23574. Epub 2011 Mar 2.

Supplemental Content

Support Center